Ontology highlight
ABSTRACT: Background
OnabotulinumtoxinA is approved as a treatment across multiple indications. For the treatment of spasticity, onabotulinumtoxinA is injected directly into affected muscles. Intramuscular injections may result in local bleeding and related complications, especially in patients receiving anticoagulant therapy. Despite anticoagulants being commonly used, there is limited information in the medical literature regarding the safety of intramuscular medications in patients receiving oral anticoagulants. This retrospective analysis included pooled safety data from Allergan-sponsored studies evaluating onabotulinumtoxinA for the treatment of patients with muscle spasticity.Objective
The objective of this study was to determine the risk of bleeding complications in patients
SUBMITTER: Dimitrova R
PROVIDER: S-EPMC7125063 | biostudies-literature | 2020 Apr
REPOSITORIES: biostudies-literature